文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

术中右美托咪定对老年腹部手术后胃肠功能恢复的影响:一项随机临床试验

Effect of Intraoperative Dexmedetomidine on Recovery of Gastrointestinal Function After Abdominal Surgery in Older Adults: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2021-10-01
一句话结论老年腹部手术术中右美托咪定输注可缩短首次排气、首次排便时间及住院时长,但不改变I-FEED评分或谵妄发生率。

该多中心、双盲、安慰剂对照RCT纳入808例60岁及以上择期腹部手术(预计手术时长1-6小时)患者,随机接受术中右美托咪定(负荷0.5 μg/kg/15分钟,维持0.2 μg/kg/h)或生理盐水。符合方案分析675例,右美托咪定组首次排气中位65小时 vs 78小时(P<.001),首次排便85小时 vs 98小时(P=.001),住院13天 vs 15天(P=.005)。I-FEED评分及术后第3天谵妄发生率两组相似。提示术中右美托咪定可能加速老年腹部手术后胃肠功能恢复。

要点

  • 老年(≥60岁)择期腹部手术、预计手术时长1-6小时者,术中右美托咪定负荷0.5 μg/kg/15分钟+维持0.2 μg/kg/h可缩短首次排气时间(中位65 vs 78小时,P<.001)。
  • 右美托咪定组首次排便时间(中位85 vs 98小时,P=.001)及住院时长(中位13 vs 15天,P=.005)均显著短于安慰剂组。
  • I-FEED评分定义的术后胃肠功能正常比例两组相似(72.1% vs 76.7%),术后第3天谵妄发生率亦无显著差异(5.2% vs 3.6%)。
  • 该研究为多中心双盲RCT,但分析采用符合方案集(排除133例方案偏离),需注意意向性分析结果未报告。

适用人群与场景

  • 年龄≥60岁、择期腹部手术且预计手术时长1至6小时的患者;多中心研究在中国安徽13家三级医院开展。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 术中静脉输注右美托咪定:负荷剂量0.5 μg/kg over 15分钟,随后维持剂量0.2 μg/kg per hour,持续至手术结束;对照组输注生理盐水。
  • 原文未提及目标值、停药指征或术后用药方案。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 多中心、双盲、安慰剂对照RCT,808例随机(右美托咪定404例,安慰剂404例),符合方案分析675例(右美托咪定344例,安慰剂331例;平均年龄70.2岁,男性65.9%)。
  • 主要终点首次排气时间:右美托咪定组中位65小时(IQR 48-78)vs 安慰剂组78小时(IQR 62-93),P<.001。
  • 首次排便时间:中位85小时(IQR 68-115)vs 98小时(IQR 74-121),P=.001。
  • 住院时长:中位13天(IQR 10-17)vs 15天(IQR 11-18),P=.005。
  • I-FEED评分提示术后胃肠功能正常者:右美托咪定组248例(72.1%)vs 安慰剂组254例(76.7%);术后第3天谵妄:18例(5.2%)vs 12例(3.6%)。
  • 原文未报告首次经口进食时间、疼痛评分、睡眠质量、术后恶心呕吐、住院费用的组间比较结果。

证据类型、等级与局限

  • 证据类型:多中心、双盲、安慰剂对照随机临床试验(RCT)。
  • 局限:分析采用符合方案集而非意向性分析(排除133例方案偏离);单国多中心;原文未报告脱落原因对结果的影响。

对床旁实践的改变

  • 对≥60岁择期腹部手术(预计1-6小时)患者,可考虑术中按原文方案输注右美托咪定以加速术后胃肠功能恢复、缩短住院时长。
  • 不应期望该方案改善I-FEED评分定义的胃肠功能或降低谵妄发生率。
  • 原文未提供不适用人群信息,临床决策需结合个体情况。

指南或共识出处

  • 原文未提及指南或共识;试验注册号:Chinese Clinical Trial Registry ChiCTR1800017232。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Postoperative ileus is common after abdominal surgery, and small clinical studies have reported that intraoperative administration of dexmedetomidine may be associated with improvements in postoperative gastrointestinal function. However, findings have been inconsistent and study samples have been small. Further examination of the effects of intraoperative dexmedetomidine on postoperative gastrointestinal function is needed.

OBJECTIVE: To evaluate the effects of intraoperative intravenous dexmedetomidine vs placebo on postoperative gastrointestinal function among older patients undergoing abdominal surgery.

DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, placebo-controlled randomized clinical trial was conducted at the First Affiliated Hospital of Anhui Medical University in Hefei, China (lead site), and 12 other tertiary hospitals in Anhui Province, China. A total of 808 participants aged 60 years or older who were scheduled to receive abdominal surgery with an expected surgical duration of 1 to 6 hours were enrolled. The study was conducted from August 21, 2018, to December 9, 2019.

INTERVENTIONS: Dexmedetomidine infusion (a loading dose of 0.5 μg/kg over 15 minutes followed by a maintenance dose of 0.2 μg/kg per hour) or placebo infusion (normal saline) during surgery.

MAIN OUTCOMES AND MEASURES: The primary outcome was time to first flatus. Secondary outcomes were postoperative gastrointestinal function measured by the I-FEED (intake, feeling nauseated, emesis, physical examination, and duration of symptoms) scoring system, time to first feces, time to first oral feeding, incidence of delirium, pain scores, sleep quality, postoperative nausea and vomiting, hospital costs, and hospital length of stay.

RESULTS: Among 808 patients enrolled, 404 were randomized to receive intraoperative dexmedetomidine, and 404 were randomized to receive placebo. In total, 133 patients (60 in the dexmedetomidine group and 73 in the placebo group) were excluded because of protocol deviations, and 675 patients (344 in the dexmedetomidine group and 331 in the placebo group; mean [SD] age, 70.2 [6.1] years; 445 men [65.9%]) were included in the per-protocol analysis. The dexmedetomidine group had a significantly shorter time to first flatus (median, 65 hours [IQR, 48-78 hours] vs 78 hours [62-93 hours], respectively; P < .001), time to first feces (median, 85 hours [IQR, 68-115 hours] vs 98 hours [IQR, 74-121 hours]; P = .001), and hospital length of stay (median, 13 days [IQR, 10-17 days] vs 15 days [IQR, 11-18 days]; P = .005) than the control group. Postoperative gastrointestinal function (as measured by the I-FEED score) and delirium incidence were similar in the dexmedetomidine and control groups (eg, 248 patients [72.1%] vs 254 patients [76.7%], respectively, had I-FEED scores indicating normal postoperative gastrointestinal function; 18 patients [5.2%] vs 12 patients [3.6%] had delirium on postoperative day 3).

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the administration of intraoperative dexmedetomidine reduced the time to first flatus, time to first feces, and length of stay after abdominal surgery. These results suggest that this therapy may be a viable strategy to enhance postoperative recovery of gastrointestinal function among older adults.

TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR1800017232.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Lu Y, Fang PP, Yu YQ, et al. Effect of Intraoperative Dexmedetomidine on Recovery of Gastrointestinal Function After Abdominal Surgery in Older Adults: A Randomized Clinical Trial. JAMA Netw Open. 2021. PMID: 34648009. doi:10.1001/jamanetworkopen.2021.28886

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。